Annals of Oncology Advance Access originally published online on March 8, 2006
Annals of Oncology 2006 17(5):769-772; doi:10.1093/annonc/mdl027
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 European Society for Medical Oncology
Clinical implications of hepatitis C virus infection in MALT-type lymphoma of the ocular adnexa
1 Medical Oncology, 2 Gastroenterology, 4 Ophthalmology, 6 Neuroradiology, and 7 Pathology Units, San Raffaele H Scientific Institute, Milan, Italy; 3 Immunovirology and Biotherapy Unit, Department of Pre-Clinical and Epidemiological Research, Centro di Riferimento Oncologico, IRCCS National Cancer Institute, Aviano, Italy; 5 Ophthalmology Unit, Ospedale San Giuseppe, Milan, Italy
* Correspondence to: Dr A. J. M. Ferreri, Medical Oncology Unit, Dept. of Oncology, San Raffaele H Scientific Institute, Via Olgettina 60, 20132 Milan, Italy. Tel: +39-02-26437649; Fax: +39-02-26437603; E-mail: andres.ferreri{at}hsr.it
Background: A pathogenic link between hepatitis C virus (HCV) and MALT-type lymphomas has been suggested. However, studies assessing the role of HCV infection separately in different forms of MALT lymphomas are not available.
Patients and methods: The prevalence and clinical implications of HCV seropositivity were analyzed in 55 patients with ocular adnexa lymphoma (OAL) of MALT-type.
Results: HCV seropositivity was detected in seven (13%) patients. At presentation, HCV infection was significantly associated with concomitant extra-orbital disease, lymph node dissemination and involvement of additional extranodal organs. HCV seropositivity was associated also with a higher relapse rate and worse progression-free survival. In fact, 16 patients experienced relapse after first-line treatment: five (71%) were HCV-seropositive and 11 (23%) were HCV-seronegative, with a median TTP of 31 and 50+ months (P = 0.01), and a 5-year progression-free survival of 43 ± 18% and 77 ± 7% (P = 0.005), respectively. HCV-seropositive patients experienced frequent relapses despite further lines of therapy; relapses were systemic in all cases but one; multiple subcutaneous nodules were common at relapse.
Conclusions: HCV seropositivity is present in 13% of OAL of MALT-type. Concomitant HCV infection is associated with more disseminated disease and aggressive behavior in OAL, with a consequent potential negative impact in patients managed with radiotherapy alone.
Key words: MALT lymphoma, ocular adnexal lymphoma, hepatitis C virus, infectious agents
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M. Paulli, L. Arcaini, M. Lucioni, E. Boveri, D. Capello, F. Passamonti, M. Merli, S. Rattotti, D. Rossi, R. Riboni, et al. Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT Ann. Onc., October 25, 2009; (2009) mdp454v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. M. Ferreri, R. Dolcetti, M.-Q. Du, C. Doglioni, A. Giordano Resti, L. S. Politi, C. De Conciliis, J. Radford, F. Bertoni, E. Zucca, et al. Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy Ann. Onc., May 1, 2008; 19(5): 835 - 846. [Abstract] [Full Text] [PDF] |
||||
![]() |
E.-K. Song, S.-Y. Kim, T. M. Kim, K.-W. Lee, T. Yun, I.-I. Na, H. Shin, S. H. Lee, D. W. Kim, S. I. Khwarg, et al. Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma Ann. Onc., February 1, 2008; 19(2): 242 - 246. [Abstract] [Full Text] [PDF] |
||||
![]() |
P Arnaud, M-C Escande, M Lecuit, P Validire, C Levy, C Plancher, A Vincent-Salomon, N Brousse, P de Cremoux, O Hermine, et al. Hepatitis C virus infection and MALT-type ocular adnexal lymphoma Ann. Onc., February 1, 2007; 18(2): 400 - 401. [Full Text] [PDF] |
||||
![]() |
L Arcaini, S Burcheri, A Rossi, M Paulli, R Bruno, F Passamonti, E Brusamolino, A Molteni, A Pulsoni, M. Cox, et al. Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT Ann. Onc., February 1, 2007; 18(2): 346 - 350. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ferreri, R Dolcetti, P Musto, G. Dognini, C Doglioni, and M Ponzoni Reply to the article 'Hepatitis C virus (HCV) infection and MALT-type ocular adnexal lymphoma (OAL)' by P. Arnaud, M.-C. Escande, M. Lecuit et al. (Ann Oncol doi:10.1093/annonc/mdl369) Ann. Onc., February 1, 2007; 18(2): 401 - 403. [Full Text] [PDF] |
||||
![]() |
A. J. M. Ferreri, M. Ponzoni, M. Guidoboni, A. G. Resti, L. S. Politi, S. Cortelazzo, J. Demeter, F. Zallio, A. Palmas, G. Muti, et al. Bacteria-eradicating therapy with doxycycline in ocular adnexal MALT lymphoma: a multicenter prospective trial. J Natl Cancer Inst, October 4, 2006; 98(19): 1375 - 1382. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Decaudin, P. de Cremoux, A. Vincent-Salomon, R. Dendale, and L. L.-L. Rouic Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options Blood, September 1, 2006; 108(5): 1451 - 1460. [Abstract] [Full Text] [PDF] |
||||


